Introduction
============

[@b6-gmb-37-194], [@b39-gmb-37-194] and [@b57-gmb-37-194] reported the first microscopic observations of human mitotic chromosomes in the late 1800s. However, decades passed before the precise modal chromosome number in humans was determined. Until [@b34-gmb-37-194], the cytogenetic analysis of chromosomes depended on spontaneously dividing cells. [@b142-gmb-37-194], using cultured embryonic cells, were the first researchers to report the correct number of human chromosomes as 46. [@b97-gmb-37-194] established an in vitro culture method for the accumulation of dividing cells using colchicine to arrest cells at metaphase. In the same year, [@b102-gmb-37-194] discovered the mitogenic property of phytohemagglutinin, resulting in further technical improvements, particularly the use of peripheral blood cells. Both events significantly increased the number of metaphase spreads available for chromosome analysis. [@b136-gmb-37-194] succeeded in culturing amniotic fluid cells and karyotyping fetal chromosomes. In the 1970s, an in vitro culture technique for chorionic villi was developed ([@b56-gmb-37-194]), and [@b99-gmb-37-194] and [@b18-gmb-37-194] improved this culture technique several years later. Cytogenetics in hematology and oncology initially used peripheral blood as a specimen due to technical difficulties in processing and culturing solid tumor tissue. Because the development of newer techniques and more adequate methods has continued to increase the resolution of chromosomes, human cytogenetics has evolved from a more basic science into a valuable strategy for diagnosing prenatal, postnatal and acquired chromosomal abnormalities. The introduction and successful application of a variety of chromosome-staining techniques in previous years and molecular cytogenetic methods in recent years has tremendously improved the number of chromosomal abnormalities described. Since the first observation of an extra copy of chromosome 21 ([@b79-gmb-37-194]) in patients with Down syndrome, many more chromosomal abnormalities, such as other trisomies, translocations, inversions, insertions, deletions, duplications and complex chromosome rearrangements, have been described. Novel methods for investigating the mechanisms underlying copy number changes, characterizing gene interactions and analyzing genes within copy number variations (CNVs) are now being explored. Because the majority of techniques have been developed to study human genomes, man has been by far the most extensively studied organism in cytogenetics. An overview of the first years of human cytogenetics and descriptions of classical and molecular cytogenetic techniques applied to the study of chromosomal abnormalities and evaluate copy number changes are discussed in more detail below.

The Beginning of Human Cytogenetics
===================================

Human cytogenetics research began in 1879 with the observations of the German pathologist Arnold, who examined carcinoma and sarcoma cells because the voluminous nuclei of these cells facilitated analysis. Later, Flemming and Hansemann were the first to examine human mitotic chromosomes. In the late 19^th^ century [@b151-gmb-37-194] proposed the word "chromosome", which means, "colored body" (from the Greek *chroma* = color and *soma* = body). The use of colchicine for chromosome preparations was first implemented in plant cytogenetics in the 1930s ([@b14-gmb-37-194]; [@b81-gmb-37-194]). This substance acts as a poison that inhibits spindle formation during mitosis, increasing the number of metaphase spreads available for analysis in a preparation. The treatment of cells with a hypotonic solution facilitated better chromosome spreading, leading to better definition for counting the chromosomes. Previous studies have shown that unspread and tangled chromosomes make it difficult to count the number of mammalian chromosomes in a preparation ([@b92-gmb-37-194]). An improved hypotonic treatment technique (hypotonic shock) was then applied to examine lung fibroblasts in human embryos, thereby establishing the correct modal number of 46 chromosomes in human diploid cells ([@b142-gmb-37-194]). In decades prior to this discovery, a human chromosome number of 48 had been described in a number of reports (see [@b44-gmb-37-194]). This number was based on an examination of chromosome preparations of human spermatogonia, which suggested that humans had 48 chromosomes ([@b103-gmb-37-194]).

Although only a few chromosome details were known during the pre-banding era, the chromosomes themselves could be arranged in different groups based on their sizes and centromere positions. Following the determination of the correct modal chromosome number, the identification of the first inherited chromosomal abnormality (aneuploidy) leading to human diseases in man was identified. [@b79-gmb-37-194] reported trisomy 21 in Down syndrome patients. Subsequently, the chromosomal abnormalities causing Klinefelter (47, XXY) and Turner (45, X) syndromes were identified ([@b41-gmb-37-194]; [@b67-gmb-37-194]). During the same period, the first acquired chromosome anomaly (Philadelphia chromosome) was described in patients with chronic myeloid leukemia ([@b102-gmb-37-194]). Subsequent technical improvements in cytogenetics included the use of phytohemagglutinin (a substance that stimulates the division of T lymphocytes in vitro) and the introduction of banding techniques at the end of the 1960s. Banding techniques use chemical treatments to produce differentially stained regions on chromosomes. The banding pattern is highly characteristic for each chromosome and facilitates the complete identification of the human karyotype.

Chromosome Banding Techniques
=============================

With the possibility of more specific identification and detailed analyses of human chromosomes, a new phase in cytogenetics began. The first method for the visualization of a pattern of bands on human chromosomes was Q-banding ([@b23-gmb-37-194]). Subsequently, G-banding ([@b128-gmb-37-194]), a technique based on the application of trypsin (a proteolytic enzyme) using Giemsa staining, was developed, and this method is still the most widespread cytogenetic method routinely used in clinical settings. Classical cytogenetics became a traditional powerful diagnostic tool for detecting genomic aberrations, including both gains and losses of segments of the genome and rearrangements within and between chromosomes. However, the resolution of standard cytogenetics techniques remained limited, with a count of approximately 400--500 bands per haploid genome ([Figure 1](#f1-gmb-37-194){ref-type="fig"}). The approaches described above facilitated the identification of structural chromosomal aberrations of at least 5--10 Mb in size. The average resolution depends on different elements, such as the optical characteristics of the microscope, the complex manner in which the DNA is packaged into chromosomes and the quality of the metaphase preparations. The resolution of the standard karyotype was improved after the introduction of high-resolution banding based on the use of synchronized lymphocyte cultures ([@b159-gmb-37-194]). Using this technique, it was possible to increase the number of cells in the pro-metaphase or prophase stages. Detailed principles, protocols and potential applications for these cytogenetic banding techniques have been summarized elsewhere ([@b152-gmb-37-194]).

Fluorescence *in situ* Hybridization (FISH) and Multiple Advances
=================================================================

The considerable gap between the limited resolution for observing chromosome structure through banding techniques (\> 5 Mb, depending on the banding resolution applied) at the light microscopy and gene levels was bridged after the introduction and application of several molecular cytogenetic approaches. The first applications of molecular techniques to chromosome slide preparations, called in situ hybridization (ISH), were attempts to identify and locate specific nucleic acid sequences inside cells or on chromosomes ([@b43-gmb-37-194]; [@b69-gmb-37-194]). The ISH technique was based on the discovery that radioactively labeled ribosomal RNA hybridized to acrocentric chromosomes. The hybridization was visualized using autoradiography, which had been applied to human chromosomes since the early 1960s ([@b46-gmb-37-194]). The use of ISH technology provided another dimension to the study of chromosomes, facilitating the visualization of DNA or complementary RNA sequences on chromosomes and in cells at the molecular level. However, the use of this method was limited due to the use of radioactive isotopes, highly repetitive DNA sequences and corresponding RNA in the satellite regions of chromosomes and centromeres ([@b105-gmb-37-194]).

Subsequently, [@b75-gmb-37-194] improved ISH with the development of a technique involving the use of a nonradioactive probe (such as biotin) for indirect labeling through nick translation. The hybridization (DNA probe and target sequence) could be visualized through avidin or streptavidin fluorescent labeling. The development of fluorescent molecules led to direct (combined with a fluorochrome) or indirect (through an intermediate molecule incorporated into a probe) binding to DNA bases, which eventually evolved into fluorescence in situ hybridization (FISH). FISH increased the resolution at which chromosome rearrangements could be identified at submicroscopic levels, making this technique applicable for both clinical diagnosis and research. FISH has been a driving force in the further development of cytogenetic techniques. The basic principle of FISH is that a target DNA in cells, nuclei or metaphase chromosomes is fixed and denatured on the surface of the slide. The probe DNA must be labeled with a nucleotide that is either conjugated to fluorescein (direct labeling) and/or a non-fluorescent hapten (indirect labeling), and the probe is first denatured and pre-hybridized with unlabeled repetitive DNA. Before hybridization, the metaphase chromosome suspension and/or interphase nuclei are enzymatically pretreated to enhance accessibility to the probe and reduce the amount of cytoplasm. The pre-treated slide containing the target and probe DNA is heated to denature the DNA. The prepared probe is subsequently applied to the slide for ∼16--48 h at 37°C for hybridization. The speed of the hybridization between the probe and the target DNA varies depending on the probe used. Post-hybridization washes remove unbound single-strand DNA and non-specifically bound DNA from the slide. When a non-fluorescent hapten is used (*e.g.*, biotin or digoxigenin), the detection occurs through a fluorescence-coupled anti-hapten. After washing, an anti-fade solution containing DAPI (4', 6-diamidino-2-phenylindole) is applied to the slide, and a coverslip must be added. DAPI is a fluorescent stain used extensively in fluorescence microscopy. FISH signals are typically observed using epifluorescence microscopes with specific filters for identifying fluorochromes ([@b90-gmb-37-194]; [@b116-gmb-37-194])), a charge-coupled device (CCD) camera captures the image and the fluorescent signals are subsequently quantified ([@b62-gmb-37-194]). The resulting images can be analyzed using commercially available systems.

Together with the development of standard FISH ([@b107-gmb-37-194],[@b108-gmb-37-194]), more sensitive FISH-based techniques were gradually developed, and several digital imaging systems were introduced for FISH image acquisition, image pre-processing and digital image analysis. FISH provides the option for the simultaneous use of one or more DNA probes, and these probes can be distinguished after labeling with different colors or color combinations. The probes primarily determine the resolution of these molecular cytogenetic techniques and can be classified according to the pattern of detected DNA sequences. Many types of probes can be used for FISH ([Figure 2](#f2-gmb-37-194){ref-type="fig"}). Currently, a range of commercial probes (*e.g.*, whole-chromosome painting probes, chromosome-arm painting probes, and repetitive centromeric, subtelomeric and locus-specific probes) is available for the detection of certain constitutional and acquired chromosomal abnormalities. Nevertheless, FISH probes can be generated through chromosome flow sorting ([@b109-gmb-37-194]) or microdissection ([@b95-gmb-37-194]) using universal degenerate oligonucleotide-primed PCR (DOP-PCR) ([@b141-gmb-37-194]).

FISH is a flexible technique that has driven the further development of other cytogenetic techniques. There are multiple approaches using FISH-based methods for different applications, *e.g.*, reverse-FISH ([@b22-gmb-37-194]), fiber-FISH ([@b40-gmb-37-194]; [@b60-gmb-37-194]), (M-FISH multicolor FISH) ([@b135-gmb-37-194]), SKY (spectral karyotyping FISH) ([@b126-gmb-37-194]), flow-FISH ([@b121-gmb-37-194]), Q-FISH (quantitative FISH) ([@b91-gmb-37-194]), COBRA-FISH (combined binary ratio labeling FISH) ([@b140-gmb-37-194]), cenM-FISH (centromere-specific M-FISH) ([@b101-gmb-37-194]), pod-FISH (parental origin determination FISH) ([@b153-gmb-37-194]), (heterochromatin-M-FISH) ([@b19-gmb-37-194]) and other modified FISH approaches. If modified, several FISH techniques can also be applied to interphase cells (interphase FISH) ([@b149-gmb-37-194]), which confers the advantages of FISH for the visualization of DNA probes in interphase nuclei ([@b28-gmb-37-194]). The limitation of standard FISH, however, is that it is not possible to simultaneously detect all of the chromosomes in the entire genome.

COBRA-FISH, M-FISH, and SKY are the most advanced FISH-based approaches, and these approaches facilitate the simultaneous visualization and detection of all human and non-human chromosomes through color karyotyping. The simultaneous staining of each of the 24 human chromosomes with a different color involves the use of whole-chromosome painting (WCP) probes, and all three of these FISH techniques use similar probe sets. Four to seven different fluorescence dyes can be used to label the WCP probes, and the chromosomes are counterstained with DAPI. The required 24 color combinations can be achieved through combinatorial or ratio labeling. The most important aspect of these techniques is the acquisition and measurement of the complete emission spectra between 400 and 800 nm, rendering a unique image that contains specific spectral information for each image point. The resulting chromosome classification is performed automatically using commercial software, and the DAPI image is also used to complement the analysis with chromosome banding information ([@b127-gmb-37-194]). A high-resolution molecular cytogenetic technique for the analysis of metaphase chromosomes, called multicolor banding (MCB), has been proposed, which involves the microdissection of chromosomal loci to obtain a set of probes that produce multicolor pseudo-G-banding ([@b86-gmb-37-194]).

For either standard or advanced FISH methods, the preparations should be analyzed using a well maintained and calibrated fluorescence microscope equipped with the optical filter sets appropriate for the fluorochromes used and an image-recording system. The development of numerous FISH protocols and multiple approaches is the result of the efforts of many diagnostic and research scientists from different research groups worldwide. These techniques have been continuously improved, and it is not possible to cover every modification of FISH in this manuscript. Detailed FISH protocols and applications are described elsewhere ([@b83-gmb-37-194]).

Comparative Genomic Hybridization (CGH) and Array-based CGH
===========================================================

The comparative genomic hybridization (CGH) technique is an efficient approach to genome-wide screening for chromosomal copy number changes (gains/duplications and losses/deletions) within a single experiment, and this technique was initially introduced to study chromosomal abnormalities that occur in solid tumors and other malignancies ([@b71-gmb-37-194]). Chromosomal CGH is based on quantitative two-color FISH and overcomes the problems of tissue culture failure and artifacts because this method is based on using tumor DNA extracted directly from either fresh or archival tumor tissue ([@b70-gmb-37-194]). The major advantage of CGH over standard FISH techniques is that only the DNA from the tumor cells is needed for analysis, avoiding the difficulties of obtaining metaphase chromosomes with good morphology and resolution for the analysis. In CGH, total genomic DNA obtained from control cells and test samples is differentially labeled using green (fluorescein isothiocyanate, FITC) and red (Texas red) fluorescent dyes, denatured, co-precipitated in the presence of blocking DNA to suppress repetitive sequences and subsequently co-hybridized to normal meta-phase chromosomes. Due to the simultaneous hybridization to normal denatured metaphase chromosome spreads, there is competition for DNA hybridization to homologous sites. After hybridization and washing, the metaphase spreads are observed under a fluorescent microscope, and image analysis is performed using image analysis software. The resulting fluorescence intensities of the test and reference hybridizations are digitally quantified along the length of each chromosome. Chromosomal regions equally represented in both the test and reference samples appear yellow because of the presence of an identical amount of red and green dye, while regions with copy number loss are red and have a ratio below one ([Figure 3a](#f3-gmb-37-194){ref-type="fig"}).

Although chromosomal CGH has increased the potential for identifying new chromosomal abnormalities, this technique is time consuming and does not significantly improve resolution (\> 3 Mb) compared with routine G-banding chromosome analysis. More recently, the development of array-based CGH (array-CGH) approaches involving the substitution of metaphase chromosomes with DNA sequences adhered onto glass slides has increased the resolution for detecting copy number changes in the human genome, leading to more detailed information on genomic gains and losses ([Figure 3b](#f3-gmb-37-194){ref-type="fig"}). Among all of the recent advances in techniques for examining chromosomes, array-CGH technology has been suggested as a technique that will gradually replace classical cytogenetics in clinical diagnosis. The fundamental principle of array-CGH is essentially the same as that in CGH. Indeed, the process involves comparative genomic hybridization using an array rather than a metaphase spread as the substrate ([@b134-gmb-37-194]; [@b110-gmb-37-194]).

The actual microarray comprises thousands of spots of reference DNA sequences applied in a precisely gridded manner on the slide. The initial arrayed DNA segments could be larger (∼150 kb) human DNA segments inserted into a bacterial artificial chromosome (BAC clones) or bacterial/P1-derived artificial chromosomes (PAC clones) ([@b133-gmb-37-194]; [@b38-gmb-37-194]; [@b25-gmb-37-194]; [@b66-gmb-37-194]). As the resolution of the array yields improves, shorter sequences have been used as targets, including smaller cDNA fragments ([@b112-gmb-37-194]), PCR products ([@b89-gmb-37-194]) and oligonucleotides ([@b120-gmb-37-194]). Furthermore, array-CGH provides resolution at the nucleotide level. Single-nucleotide polymorphism arrays (SNP arrays) have the highest resolution (5--10 kb) of all of the available array-based platforms (see [@b77-gmb-37-194]). The co-hybridization of the test and reference DNAs is not required because the test DNA can hybridize directly to the SNP array. In addition to CNVs, the genotype information obtained from SNP arrays enables the detection of stretches of homozygosity and thus the identification of recessive disease genes, mosaic aneuploidy or uniparental disomy (UPD) ([@b31-gmb-37-194]). While only SNP arrays enable the detection of copy number-neutral regions in the absence of heterozygosity (AOH), these arrays have limited ability to detect single-exon copy CNVs due to the distribution of SNPs across the genome. Combining both array-CGH and SNP genotyping in a single platform optimizes the clinical diagnostic capability, offering the simultaneous detection of copy number neutral and small intragenic copy number changes ([@b157-gmb-37-194]).

The number, size and distribution of the DNA segments on the glass slide determine the array resolution, but commonly, the higher the number of DNA fragments, the higher the resolution. According to [@b9-gmb-37-194] and [@b24-gmb-37-194], array-CGH also has increased the sensitivity for detecting cell lines with chromosomal abnormalities in peripheral blood, as chromosomal abnormalities are typically detected in only 5--7% of cells. Currently, there are several different commercially available diagnostic DNA microarray platforms comparing thousands of DNA sequences from a patient sample with reference (control) DNA samples or control datasets to detect chromosomal CNVs. A common limitation of SNP and CGH arrays is the inability to identify balanced translocations and inversions.

Recently, a modified array protocol, called translocation CGH (tCGH), was developed to address recurrent translocation breakpoints in hematological neoplasms. Prior to the hybridization step in the array procedure, a linear PCR amplification is performed across the known recurrent translocation breakpoints in hematological neoplasms. Thus, it is possible to detect copy number changes and known recurrent translocations near or at the breakpoints ([@b54-gmb-37-194]). Custom-made commercial arrays that use general standard protocols can also be ordered. Detailed information on the protocols and references is available elsewhere ([@b10-gmb-37-194]).

FISH Applications in Pre- and Postnatal Diagnostics and Research
================================================================

Several decades ago, molecular methods were introduced into cytogenetic studies, facilitating the development of new applications, many of which were used diagnostically or as prognostic tools in medicine. Furthermore, molecular cytogenetic approaches have also become indispensable for a range of research purposes. The use of molecular techniques in cytogenetic studies is increasing, and the many variations, adaptations and specifications make it challenging to cover all of the possible applications. Since the introduction of FISH in the late 1980s, there has been a tremendous increase in the number of studies using molecular approaches in cytogenetics to detect chromosomal abnormalities and evaluate CNVs in the human genome. FISH offers numerous possibilities for studying either the whole genome or specific genomic loci (regions), and this technique has been widely used to detect aneuploidies and recurrent chromosomal abnormalities in preimplantation genetic, prenatal, and postnatal diagnoses and cancer cytogenetics. Moreover, the application of FISH has long been demonstrated as extremely valuable for studying chromosomal and genome organization, evolution and variations in health and disease (see [@b47-gmb-37-194]; [@b94-gmb-37-194]; [@b111-gmb-37-194]).

A significant advantage of FISH is that it can be applied in non-dividing cells, thereby facilitating the direct investigation of chromosomes in cytological preparations and tissue sections. Classical cytogenetic analysis depends on cells undergoing mitosis to obtain metaphase chromosome spreads. Therefore, cells must be cultured in vitro either as a short- or long-term culture. Thus, interphase FISH on uncultured amnion cells has become a useful method for the rapid and early diagnosis of the most common chromosome disorders (trisomies 21, 13, 18 and sex chromosome aneuploidies) in fetal cells ([@b35-gmb-37-194]). For prenatal aneuploidy screening using uncultured amniocytes, no time-consuming cell culture is required, and the results can be obtained within 24--48 hours. Three satellite centromeric probes for chromosomes X, Y and 18 and two locus-specific probes for the 13q14 and 21q22.13 regions are the most commonly applied. Interphase FISH in prenatal diagnosis is a quick, accurate, sensitive and relatively specific method to detect aneuploidies in samples of uncultured chorionic villus ([@b119-gmb-37-194]) and amniotic fluid cells ([@b138-gmb-37-194]).

Using site-specific DNA probes (YACs, BACs, PACs, and cosmids), FISH is typically applied for mapping chromosomal regions with located breakpoints ([@b83-gmb-37-194]). In addition, using locus-specific probes, FISH has also been used to confirm clinical diagnoses of known microdeletion and microduplication syndromes (Riegel and coworkers, unpublished data). However, FISH has limitations in the detection of known microdeletion syndromes. Occasionally, patients with small and unusual deletions might escape detection, depending on the specificity of the fluorescent probe. Moreover, cases with gene or imprinting mutations, occurring in some microdeletion syndromes, *e.g.*, Angelman syndrome (AS), Prader-Willi syndrome (PWS), Sotos syndrome (SoS), Miller-Diecker syndrome (MDS), Smith-Magenis syndrome (SMS) and Rubinstein-Taybi syndrome (RTS), cannot be detected through FISH. The analysis of telomeres using FISH techniques has been conducted in cancer and aging research (telomere biology); however, due to the lack of specificity of the DNA probes (TTAGGG repetitive sequence motifs), this technique is poorly applicable for diagnosis ([@b7-gmb-37-194]). Multicolor FISH approaches have been most valuable for cancer cytogenetics, but these methods have also been applied to diagnose constitutional chromosomal abnormalities ([@b87-gmb-37-194]) and define translocations and marker chromosomes in complex karyotypes ([@b73-gmb-37-194]).

Applications of CGH Analysis
============================

Although CGH has primarily been applied to study solid tumors, this technique has also used to study leukemia and lymphoma ([@b71-gmb-37-194]; [@b42-gmb-37-194]; [@b45-gmb-37-194]; [@b21-gmb-37-194]). However, given that CNVs are associated with many conditions, ranging from cancer to developmental abnormalities, CGH has also been applied to identify constitutional chromosomal abnormalities in clinical samples ([@b30-gmb-37-194]; [@b80-gmb-37-194]; [@b74-gmb-37-194]; [@b98-gmb-37-194]; [@b125-gmb-37-194]). Several reports have demonstrated the use of either standard CGH or array-CGH to detect chromosomal abnormalities in single cells of pre-implantation embryos ([@b156-gmb-37-194]; [@b76-gmb-37-194]; [@b58-gmb-37-194]).

Array-CGH was initially applied to identify chromosomal imbalances through the detection of CNVs in tumors to distinguish candidate genes involved in the pathogenesis of cancer ([@b20-gmb-37-194]; [@b3-gmb-37-194]). In clinical diagnostics, both oligonucleotide array-CGH and SNP genotyping have been demonstrated as powerful genomic technologies for evaluating idiopathic mental retardation (MR) (also referred to as developmental delay (DD), intellectual disability (ID) or learning difficulty), associated congenital abnormalities (MCA), autistic spectrum disorders (ASDs), schizophrenia and other neuropsychiatric disorders. Furthermore, the introduction of genome-wide array platforms facilitated the detection of chromosomal abnormalities consistent with genetic syndromes at earlier ages, when only a few clinical findings might be present.

CNVs are DNA segments that present a variable copy number compared with a reference genome, which has the typical copy number of N = 2 ([@b37-gmb-37-194]). In 2004, two studies employing array-based platforms revealed that CNVs exist in many large DNA genomic segments between normal human individuals, suggesting that these variations are fairly common and might represent polymorphic variations and a significant source of genetic variation ([@b64-gmb-37-194]; [@b129-gmb-37-194]). Furthermore, the examination of the genomic content of CNVs revealed that these genomic regions include many functional genes involved in the regulation of cell growth and metabolism ([@b64-gmb-37-194]), implicating CNVs in human traits, disease and evolution. Since that time, many additional studies using a multitude of different high-resolution genome-analysis platforms have advanced our knowledge regarding CNVs.

Since [@b148-gmb-37-194] published the first report on detecting constitutional submicroscopic imbalances using array-based techniques in a series of patients with ID/MCA, the results of many more array-based studies have been published. Array-based genome investigations have been demonstrated to detect pathogenic imbalances in approximately 14--18% of consecutive ID/MCA cases referred for analysis. The rate differences might reflect differences in the resolutions of the array platforms used, the criteria for patient selection and the interpretation of the clinical relevance of the CNVs detected. Most of these CNVs are deletions and duplications that arise de novo, either as unique or recurrent events ([@b63-gmb-37-194]). The increasing number of laboratories worldwide applying array-based methods for the diagnosis of patients with multiple congenital abnormalities has increased the detection of human genomic imbalances and led to the identification of a number of diseases caused by chromosomal microdeletions and microduplications. In recent years, common and newer microdeletion and microduplication syndromes associated with a variety of phenotypes have been revisited ([@b124-gmb-37-194]; Riegel and coworkers, unpublished data;) and recognized ([@b32-gmb-37-194]; [@b115-gmb-37-194]; [@b147-gmb-37-194]; [@b154-gmb-37-194]; [@b131-gmb-37-194]).

The use of array-CGH as a genetic test in selected sporadic ASD patients has shown that non-syndromic, de novo CNVs occur in ∼7.5% of boys and ∼12% of girls. De novo deletions CNVs in female patients tend to be larger than in male patients and contain a higher number of protein-coding genes ([@b122-gmb-37-194]). According to [@b63-gmb-37-194], these findings suggest that women are more resistant than men to developing ASD and are less likely to be diagnosed with ASD or both. In syndromic ASD cases, the chance of finding a causal CNV is nearly 25%. Based on recurrent microdeletions and microduplications identifiable on array-based platforms, a contributing CNV can be expected in approximately 5% of patients with schizophrenia. This rate only considers the currently known CNVs. Thus, it is likely that many more unique CNVs with major effects exist, similarly to ASD. In a small fraction of patients with schizophrenia, the alleles with CNVs are likely the strongest factors contributing to the pathogenesis of the disease ([@b137-gmb-37-194]).

Recently, [@b100-gmb-37-194] reported the frequency of pathogenic chromosomal microdeletions and microduplications in a large group of referred patients with developmental delay (DD), intellectual disability (ID) or autism spectrum disorders (ASD), and these authors provided a genetic diagnostic service. The first tier testing was applied using a standardized oligo-array CGH platform. The following detection rates, excluding the CNVs of uncertain significance, were observed: DD (13.0%), ID (15.6%), ASD (2.3%), ASD with DD (8.2%), ASD with ID (12.7%) and unexplained epilepsy with DD, ID and ASD (10.9%). Greater diagnostic sensitivity reflects the routine application of array CGH, compared with previously used conventional cytogenetics; according to [@b100-gmb-37-194], the greater diagnostic sensitivity outweighs the interpretative issues arising from the detection of CNVs of uncertain significance.

Microarray approaches are increasingly used in prenatal settings in pregnancies with ultrasound anomalies and pregnancies referred for other reasons. However, challenges in interpreting the results, quality control and ethical issues have delayed the use of microarray approaches in prenatal care compared with postnatal diagnoses ([@b117-gmb-37-194]; [@b146-gmb-37-194]). Numerous case series and case reports have since been published on the application of array-CGH in prenatal settings ([@b16-gmb-37-194]; [@b17-gmb-37-194]; [@b36-gmb-37-194]). Array-CGH increases the diagnostic yield for detecting additional genomic imbalances 1--5% compared with normal karyotyping, depending on the reference source ([@b2-gmb-37-194]; [@b61-gmb-37-194]; [@b82-gmb-37-194]).

In hematologic and oncologic disorders, the implementation of array-based chromosome analysis has been critical. The complexity of cancer cells requires a sensitive technique that facilitates the detection of small genomic changes in a mixed cell population and segmental regions of homozygosity. However, recurrent balanced genomic aberrations with important prognostic value in cancer might be not detected through array-based analyses. Because array-CGH is based on the principle of CNV detection, this technique is limited by an inability to identify balanced translocations and inversions. Nevertheless, arrays have been previously demonstrated as clinically essential for identifying novel genomic abnormalities that escape detection using current diagnostic methodologies in a number of hematological diseases, such as chronic lymphocytic leukemia (CLL), myelodysplastic syndrome (MDS), multiple myeloma (MM), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) ([@b130-gmb-37-194]; [@b132-gmb-37-194]). Moreover, the identification and accurate genomic mapping of genomic alterations in hematological malignances in a preclinical stage have shown that it is possible to refine the current risk stratification of patients, and this technique might eventually contribute to the development of enhanced treatment modalities ([@b143-gmb-37-194]; [@b132-gmb-37-194]).

The detection of common and rare CNVs using array-based platforms has generated questions concerning the origin and molecular mechanisms leading to recurrent and non-recurrent CNVs ([@b88-gmb-37-194]; [@b29-gmb-37-194]; [@b33-gmb-37-194]; [@b139-gmb-37-194]) and the phenotypic effects of CNVs and recurrence risks ([@b53-gmb-37-194]; [@b113-gmb-37-194]; [@b15-gmb-37-194]). Recombination-based mechanisms, *i.e.*, non-allelic homologous recombination (NAHR), non-homologous end joining (NHEJ) ([@b88-gmb-37-194]) and retrotransposition ([@b72-gmb-37-194]; [@b158-gmb-37-194]), have been implicated in genomic rearrangements and the formation of CNVs. A replication-based mechanism, fork stalling and template switching (FoSTeS) might account for the complex genomic rearrangements that cannot be readily explained through NAHR, NHEJ or retrotransposition ([@b78-gmb-37-194]; [@b106-gmb-37-194]; [@b5-gmb-37-194]). CNVs represent an important component of genetic variation and have been described as a major contributor to phenotype diversity and disease ([@b50-gmb-37-194]; [@b4-gmb-37-194]; [@b27-gmb-37-194]; [@b52-gmb-37-194]; [@b49-gmb-37-194]).

Interpretation of CNVs
======================

The widespread use of array-CGH has revealed that a large proportion of the human genome contains regions of copy number variability, and distinguishing between pathogenic and benign gains and losses has been challenging. Although array-CGH technology has been well developed and there are numerous algorithms available for estimating copy number ([@b93-gmb-37-194]), the resolution of the array platforms used in molecular cytogenetics and our understanding of the clinical effects of CNVs are still improving. Recurrent CNVs can occur in both patients and healthy individuals, and frequently, more than one unique CNV is identified in a patient. A given copy number change with a high penetrance pathogenic might reduce or aggravate the clinical phenotype in the presence of other CNVs/SNPs. For example, [@b50-gmb-37-194] demonstrated that the 16p11.2 microdeletion predisposes individuals to neuropsychiatric phenotypes as a single event and aggravates neurodevelopmental phenotypes in association with other large deletions or duplications within the genome of an individual.

The large quantity of clinical and cytogenetic data available in open access databases can help decipher which combinations of variants lead to varying degrees of pathogenicity. Factors that influence the pathogenicity of CNVs and an evidence-based classification for the clinical interpretation of CNVs have been discussed and proposed ([@b78-gmb-37-194]; [@b59-gmb-37-194]; [@b96-gmb-37-194]; [@b48-gmb-37-194]; [@b31-gmb-37-194]; [@b118-gmb-37-194]; [@b85-gmb-37-194]). Online resources and public databases have been developed and are utilized by the scientific and biomedical community, which has been encouraged to submit cases to the databases to provide data on the test results ([@b150-gmb-37-194]).

Common strategies have been proposed to help interpret CNV findings, and no universal criteria have been established thus far. Most laboratories classify the various CNVs into different categories using some or all of the CNV classifications: benign CNV or normal genomic variant; benign CNV; CNV with uncertain clinical relevance or variants of uncertain significance (VOUS); and CNV with potential clinical relevance or pathogenic variants. When array-CGH was initially used, all identified CNVs were generally reported. In recent years, the trend towards standardizing the reporting among laboratories worldwide, and the current tendency is to report only potentially meaningful CNVs. Nevertheless, the array platform used and the reporting criteria might vary between individual laboratories. Different laboratories might also use different methods to confirm the array findings (*e.g.*, FISH, multiplex ligation-dependent probe amplification (MLPA), Quantitative Fluorescence Polymerase Chain Reaction (QF-PCR), and a second array-CGH).

When interpreting and classifying CNVs, it is essential to distinguish gains from losses because the potential clinical consequences might significantly differ. Furthermore, it is essential to compare gains with gains and losses with losses ([@b144-gmb-37-194]; [@b26-gmb-37-194]; [@b145-gmb-37-194]). [@b31-gmb-37-194] summarized the characteristics of the most commonly used Internet databases and resources and proposed a general interpretation strategy that can be used for comparative hybridization, comparative intensity and genotype-based array data. Some of the available online databases associated with chromosome abnormalities and variants are listed below (as of January 2014): Centre for the Development and Evaluation of Complex Interventions for Public Health Improvement (DECIPHER) project: <http://decipher.sanger.ac.uk>.The Chromosome Anomaly Collection: <http://www.ngrl.org.uk/wessex/collection/>.Chromosomal Variation in Man Online Database: <http://www.wiley.com/legacy/products/subject/life/borgaonkar/access.html>.Cytogenetic Data Analysis System (CyDAS): <http://www.cydas.org/>.Database of genomic structural variation (bdVar): <http://www.ncbi.nlm.nih.gov/dbvar/>.Ensembl: [www.ensembl.org/](www.ensembl.org/).European Cytogeneticists Association Register of Unbalanced Chromosome Aberrations (ECARUCA): [www.ecaruc.net](www.ecaruc.net).The International Standards for Cytogenomic Arrays (ISCA) Consortium:<https://www.iscaconsortium.org/index.php>.Small supernumerary marker chromosomes: <http://ssmc-tl.com/sSMC.html>.

Final Remarks
=============

The methods described herein provide information on the human genome at different levels of resolution and have shown potential for diagnostic and research purposes. The resolution for studying chromosomes has improved from \> 5 Mb (metaphase) to 50 kb-2 Mb (interphase) and 5--500 kb (DNA fibers) and ultimately, to a single nucleotide. Molecular cytogenetics and array-based technologies facilitate higher resolutions through genome-wide screening for submicroscopic genomic CNVs. However, to identify cytogenetically visible CNVs (*e.g.*, heterochromatin), low mosaicisms and balanced translocations, banding cytogenetics has been demonstrated as useful. Cytogenetic testing in developed countries primarily uses array-CGH technology to detect novel or rare microdeletions/microduplications and has become the first-line test in the diagnostic investigation of individuals with MCAs, DDs or unexplained IDs. Although the use of banding and FISH has gradually been replaced by array-based technologies in several laboratories, G-banding remains the most commonly used approach worldwide to study the human genome. Moreover, the comparison of chromosome and array-based chromosome analyses has demonstrated that chromosome analysis remains valuable for detecting mosaicisms and to delineate chromosomal structural rearrangements ([@b12-gmb-37-194]). Evaluating the use of conventional karyotypes or molecular approaches will likely require continuous evaluation, as questions regarding how to achieve cost-effective diagnoses still remain in many clinical situations, *e.g.*, rare chromosome breakage syndromes and low-risk pregnancies (van Ravenswaaij-Arts, personal communication 2013).

As the number of recognized genetic syndromes and chromosomal abnormalities grows and as the clinical characteristics of those syndromes overlap, it will be more difficult to precisely infer which syndrome affects an individual based only on the clinical examination. Currently, the detection of large numbers of CNVs using molecular cytogenetic approaches in patients and healthy individuals has been considered a diagnostic pitfall due to interpretation difficulties. Most chromosomal abnormalities have clinical effects; however, the number of instances in which genomic changes are benign has increased, as the resolution of chromosome analysis has also increased. In clinical diagnosis, both array-CGH and SNP genotyping have been demonstrated as powerful genomic technologies to evaluate DD, MCAs and neuropsychiatric disorders. Differences in the ability to detect genomic changes between these arrays might constitute a challenge for laboratory managers, as the request to provide the best approach to detect underlying genetic causes of diseases is increasing. In most cases, imbalances that are cytogenetically visible in size (several Mb) lead to severe clinical consequences and are responsible for specific syndromes or clinical features ([@b123-gmb-37-194]). However, CNVs can be expected in every individual on a chromosomal or molecular genetic level ([@b1-gmb-37-194]). Thus, it is expected that the identification of variants of unknown clinical significance will significantly increase, particularly as many individuals now have their entire genomes sequenced ([@b8-gmb-37-194]; [@b104-gmb-37-194]). Segmental chromosome regions that might be present in variable copy numbers in the genome without phenotypic consequences are constantly being identified ([@b11-gmb-37-194]; [@b84-gmb-37-194]).

To date, the critical point has been to distinguish similar-looking benign imbalances from pathological imbalances. To facilitate the interpretation and analysis of the information obtained using molecular cytogenetic approaches, widely available public databases have been developed and are constantly updated (*e.g.*, CyDAS, DECIPHER, ECARUCA, ISCA). Nevertheless, many genomic imbalances are novel or extremely rare, making interpretation problematic and uncertain. Thus, further molecular cytogenetic screenings of large patient cohorts with common phenotypic features contribute to the ongoing development of genotype-phenotype correlations, identifying CNVs in dosage-sensitivity genes and defining their locations in the human genome. The use of whole-genome sequencing and whole-exome sequencing platforms has been increasingly popular and powerful for genetic diagnosis ([@b13-gmb-37-194]; [@b55-gmb-37-194]; [@b68-gmb-37-194]; [@b114-gmb-37-194]). These methods might potentially be alternatives to the use of microarrays in molecular cytogenetic laboratories. The technologies applied to study genomic imbalances have been rapidly changing. Therefore, the comprehensive collection, organization and maintenance of the raw genotype-phenotype data obtained through different approaches are major challenges.

The implementation and updating of national, regional and international guidelines on the indications and interpretations of molecular cytogenetics results along with clinical management to improve expertise and experience in clinical and laboratory praxis are necessary to improve scientific knowledge and medical care. In addition, the reporting of molecular cytogenetic results is also another important issue ([@b65-gmb-37-194]). As new techniques are implemented in cytogenetic laboratories for clinical use, additional provisions for reporting findings should be developed though international guidelines. The number of chromosomal abnormalities and potential genomic rearrangements in the human genome are likely unlimited. In the last decade, the importance of both high-quality cytogenetics and genome sequencing for detecting and understanding the molecular mechanisms that lead to these chromosomal changes has been clear. Regardless of the development of next-generation molecular techniques for identifying chromosomal imbalances and CNVs in the human genome, the essential purpose of cytogenetics will remain the same: to study genomic organization and the structure, function and evolution of chromosomes.

The author would like to apologize to those colleagues whose contributions to the field have been unwittingly omitted and to the authors of relevant papers who could not be cited because of space limitations. Unpublished results were generally not included except as personally observed by the author.

![Human Karyotype. GTG-banded male patient with a normal metaphase spread with approximately 550 bands.](gmb-37-194-g001){#f1-gmb-37-194}

![FISH with different types of probes and partial metaphases. (a) Whole chromosome 21 painting; (b) partial chromosome painting probe for the long arm of chromosome 9; (c) locus-specific probe for chromosome 4p16.3 (red) and Alfa satellite probe 4p11-q11(green); (d) subtelomeric probe for the short arm (red) and long arm (green) of chromosome 1; (e) human telomeric probes; and (f) Interphase-FISH with locus-specific SRY (sex-determining region Y) probe located in Yp11.31(red) and control probes for the X centromere (DXZ1) (blue) and for the heterochromatic block at Yq12 (green).](gmb-37-194-g002){#f2-gmb-37-194}

![Comparative Genomic Hybridization. (A) Conventional CGH analysis: a mixture of test DNA from a patient and a normal reference DNA labeled with different fluorochromes are hybridized to normal chromosome spreads (*top panel*). The left panel illustrates the hybridization pattern of chromosome 13. The interstitial segment of q-arm appears red, which indicates a loss of the region indicating rev ish dim (13q21q31). The right panel shows a graph of the ratio profiles of chromosome 13. The black line represents the balanced fluorescence intensities, and the red line is the threshold for loss, and the green line is the threshold for a gain of material. (B) Chromosome 4 array-CGH profile of a test DNA and a reference DNA. The figure shows a copy number loss corresponding to the segment of 4p16.3-p15.33 in a genomic segment with the median log2 ratio shifted to −1.0. The lower panel shows the 4p16.3-p15.33 region with the deletion segment and the genes present in this region.](gmb-37-194-g003){#f3-gmb-37-194}
